Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Overall Survival
42%
Chemotherapy
34%
Ramucirumab
31%
Placebo
30%
Neoplasm
30%
Progression Free Survival
24%
Alpha Fetoprotein
24%
Sorafenib
24%
Adverse Event
22%
Paclitaxel
20%
Irinotecan
18%
Gemcitabine
17%
Malignant Neoplasm
17%
Pembrolizumab
15%
Cetuximab
15%
Pancreas Adenocarcinoma
15%
Hepatitis B Virus
14%
Fluorouracil
14%
Cisplatin
13%
Folinic Acid
13%
Immunoreactive Insulin
13%
Head and Neck Squamous Cell Carcinoma
13%
Pancreas Cancer
12%
Atezolizumab
12%
Solid Malignant Neoplasm
11%
Nasopharynx Carcinoma
10%
Recurrent Disease
10%
Liver Cancer
10%
Oxaliplatin
9%
Programmed Death 1 Ligand 1
9%
Biological Marker
9%
Epidermal Growth Factor Receptor
9%
Bevacizumab
9%
Head and Neck Cancer
9%
Inflammation
9%
microRNA
9%
Diseases
9%
Clinical Trial
9%
Polyethylene Glycol
8%
Prevalence
7%
Nivolumab
7%
Phase II Trials
7%
Randomized Clinical Trial
6%
Abdominal Cancer
6%
Tislelizumab
6%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
6%
Esophageal Squamous Cell Carcinoma
6%
Esophageal Adenocarcinoma
6%
Codrituzumab
6%
Medicine and Dentistry
Hepatocellular Carcinoma
67%
Overall Survival
35%
Ramucirumab
22%
Sorafenib
17%
Neoplasm
16%
Placebo
16%
Head and Neck Cancer
15%
Malignant Neoplasm
12%
Cetuximab
12%
Arm
12%
Gemcitabine
11%
Carcinoma Cell
10%
Adverse Event
10%
Betel
9%
Progression Free Survival
9%
Elevated Alpha-Fetoprotein
9%
Nivolumab
9%
Pembrolizumab
9%
Head and Neck Squamous Cell Carcinoma
9%
Pancreas Cancer
9%
Pancreas Adenocarcinoma
9%
Hazard Ratio
9%
Hepatitis B Virus
8%
Liver Cancer
8%
microRNA
8%
Nasopharynx Carcinoma
7%
Biological Marker
7%
Recurrent Disease
7%
Clinical Trial
7%
Prevalence
6%
Prognostic Factor
6%
Neck
6%
Diseases
6%
Metastatic Carcinoma
6%
Cisplatin
6%
Oral Hygiene
6%
Chemoradiotherapy
6%
Esophageal Squamous Cell Carcinoma
6%
Glycon
6%
Irinotecan
6%
Autophagy
6%
Endoscopic Ultrasound
6%
Maspin
6%
Polyethylene Glycol
6%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
6%
Biliary Tract Cancer
6%
Cancer
6%
Cohort Analysis
5%
Odds Ratio
5%
Alcohol Consumption
5%
Keyphrases
Advanced Hepatocellular Carcinoma
18%
Ramucirumab
15%
Sorafenib
13%
Head-and-neck Cancer
12%
Overall Survival
10%
Alpha-fetoprotein
9%
Taiwanese
9%
Metastatic Pancreatic Ductal Adenocarcinoma
7%
First-line Therapy
6%
Liposomal Irinotecan
6%
Atezolizumab
6%
Nivolumab
6%
Phase III Clinical Trial
6%
CheckMate
6%
Recurrent Squamous Cell Carcinoma
6%
Hepatocellular Carcinoma Cells
6%
Autophagy Pathway
6%
Recurrent or Metastatic
6%
AMP-activated Protein Kinase
6%
Cancer Patients
6%
Second-line Treatment
6%
Real-world Experience
6%
Metformin
6%
Sorafenib-resistant Hepatocellular Carcinoma
6%
Patient-centered Outcomes
6%
Therapy Choice
5%
Epidermal Growth Factor Receptor
5%
Hazard Ratio
5%
Autophagy
5%